University Of Alabama at Birmingham is a clinical research site located in Birmingham, Alabama, United States 35233.
Crixeo Health Trust Score: 71/100 (FAIR). This profile has not yet been claimed by the site owner.
University Of Alabama at Birmingham has participated in 6 clinical trials.
Therapeutic areas: HER2 Positive Breast Cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer, HER-2 Positive Breast Cancer.
Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer, UNC Lineberger Comprehensive Cancer Center.
Trust Score: 71/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
University Of Alabama at Birmingham has a Crixeo Trust Score of 71/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
University Of Alabama at Birmingham has 6 clinical trials on record. Their work covers HER2 Positive Breast Cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer, HER-2 Positive Breast Cancer.
Yes — University Of Alabama at Birmingham holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.